Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy

被引:4
作者
Di Perri, G
Vento, S
Mazzi, R
Bonora, S
Bonora, A
Trevenzoli, M
Allegranzi, B
Carretta, G
Lanzafame, M
Pizzighella, S
Concia, E
机构
[1] Univ Verona, Inst Immunol & Infect Dis, I-37100 Verona, Italy
[2] Univ Verona, Inst Ophthalmol, I-37100 Verona, Italy
[3] Univ Verona, Div Microbiol, I-37100 Verona, Italy
关键词
D O I
10.1016/S0163-4453(99)90048-8
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: To see whether in severely immunosuppressed AIDS patients (with prior Cytomegalovirus retinal disease) who have significant increases in CD4+ lymphocytes following the initiation of highly active antiretroviral therapy (HAART) anti-Cytomegalovirus (CMV) maintenance therapy can be withdrawn with no subsequent progression of CMV retinitis. Methods: Eight patients with AIDS and one or more previous episodes of CMV retinitis interrupted anti-CMV maintenance therapy following the successful beginning of HAART. CD4 cell counts and HIV-RNA were monitored monthly while measurement of CMV antigenemia and ophthalmoscopy were carried every 2 weeks thereafter. Results: The HAART recipients in whom anti-CMV maintenance therapy had been interrupted had measureable increases of CD4+ T lymphocytes, substantial control of both HIV-RNA and CMV viraemia and did not show recurrence of retinitis during a mean follow-up of 98.4 weeks (range 78-120, SD 15.2). Conclusions: Anti-CMV maintenance therapy can be interrupted with no subsequent progression of retinal damage over a long time in patients with AIDS who successfully respond to HAART with a significant increase in CD4 cell count. (C) 1999 The British Infection Society.
引用
收藏
页码:193 / 197
页数:5
相关论文
共 30 条
[1]  
*CDCP, 1997, MMWR-MORBID MORTAL W, V46, P22
[2]  
CONTRILL HL, 1989, OPHTHALMOLOGY, V96, P367
[3]   Highly active antiretroviral therapy [J].
Di Perri, G ;
Bonora, S ;
Vento, S ;
Allegranzi, B ;
Concia, E .
LANCET, 1998, 351 (9108) :1056-1056
[4]   HIGH-DOSE INTRAVITREAL FOSCARNET IN THE TREATMENT OF CYTOMEGALOVIRUS RETINITIS IN AIDS [J].
DIAZLLOPIS, M ;
ESPANA, E ;
MUNOZ, G ;
NAVEA, A ;
CHIPONT, E ;
CANO, J ;
MENEZO, JL ;
ROMERO, FJ .
BRITISH JOURNAL OF OPHTHALMOLOGY, 1994, 78 (02) :120-124
[5]   CYTOMEGALOVIRUS (CMV) ANTIGENEMIA ASSAY IS MORE SENSITIVE THAN SHELL VIAL CULTURES FOR RAPID DETECTION OF CMV IN POLYMORPHONUCLEAR BLOOD LEUKOCYTES [J].
ERICE, A ;
HOLM, MA ;
GILL, PC ;
HENRY, S ;
DIRKSEN, CL ;
DUNN, DL ;
HILLAM, RP ;
BALFOUR, HH .
JOURNAL OF CLINICAL MICROBIOLOGY, 1992, 30 (11) :2822-2825
[6]   HIV-protease inhibitors [J].
Flexner, C .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (18) :1281-1292
[7]   INCIDENCE AND NATURAL-HISTORY OF CYTOMEGALOVIRUS DISEASE IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE TREATED WITH ZIDOVUDINE [J].
GALLANT, JE ;
MOORE, RD ;
RICHMAN, DD ;
KERULY, J ;
CHAISSON, RE ;
BARTLETT, J ;
MCAVINUE, S ;
BRYSON, Y ;
COHEN, H ;
FISCHL, M ;
BOLIN, T ;
KESSLER, H ;
BURROUGH, Y ;
MILDVAN, D ;
FOX, A ;
RICHMAN, D ;
FREEMAN, B ;
SIMON, G ;
GRABOWY, KW ;
CHERNOFF, D ;
DUFF, P ;
THOMPSON, S ;
BARRETT, K ;
AWE, R ;
CHAPMAN, R ;
LEONARD, S ;
BAINES, L ;
TURNER, P ;
HAWKINS, M ;
MURRAY, H ;
BOWERS, J ;
LANE, C ;
TILSON, H ;
ANDREWS, E ;
SMILEY, L .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (06) :1223-1227
[8]   PROGRESSION RATES OF CYTOMEGALOVIRUS RETINOPATHY IN GANCICLOVIR-TREATED AND UNTREATED PATIENTS [J].
HOLLAND, GN ;
SHULER, JD .
ARCHIVES OF OPHTHALMOLOGY, 1992, 110 (10) :1435-1442
[9]  
Jabs D A, 1995, Trans Am Ophthalmol Soc, V93, P623
[10]  
JABS DA, 1992, NEW ENGL J MED, V326, P213, DOI 10.1056/NEJM199201233260401